当前位置:首页 - 行情中心 - 华兰生物(002007) - 财务分析 - 现金流量表

华兰生物

(002007)

  

流通市值:208.02亿  总市值:241.36亿
流通股本:15.74亿   总股本:18.26亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,147,276,910.29819,616,146.734,451,476,719.53,056,450,334.04
  收到的税费返还43,615,704.1339,179,943.62,333,182.08-
  收到其他与经营活动有关的现金31,747,435.6624,077,141.7963,444,684.5349,577,991.22
  经营活动现金流入小计2,222,640,050.08882,873,232.124,517,254,586.113,106,028,325.26
  购买商品、接受劳务支付的现金992,572,229.54475,978,555.51,623,341,704.861,201,832,710.1
  支付给职工以及为职工支付的现金277,728,469.67152,873,951.85498,704,992.81376,796,113.02
  支付的各项税费252,519,565.37135,377,471.06398,199,167.11295,882,306.07
  支付其他与经营活动有关的现金357,093,959.02125,032,833.141,119,052,221.08780,888,381.48
  经营活动现金流出小计1,879,914,223.6889,262,811.553,639,298,085.862,655,399,510.67
  经营活动产生的现金流量净额342,725,826.48-6,389,579.43877,956,500.25450,628,814.59
二、投资活动产生的现金流量:
  收回投资收到的现金5,797,844,776.272,601,724,646.2912,224,906,537.789,476,763,328.53
  取得投资收益收到的现金90,132,898.3376,856,763.87264,014,024.63195,988,242.71
  处置固定资产、无形资产和其他长期资产收回的现金净额291,070.8569,782.622,685,413.56480,068.65
  处置子公司及其他营业单位收到的现金净额1,574,940.1---
  投资活动现金流入小计5,889,843,685.552,678,651,192.7812,491,605,975.979,673,231,639.89
  购建固定资产、无形资产和其他长期资产支付的现金79,212,547.7551,713,943.75197,305,265.37148,340,438.42
  投资支付的现金5,006,000,0002,063,000,00011,760,017,908.48,788,517,908.4
  投资活动现金流出小计5,085,212,547.752,114,713,943.7511,957,323,173.778,936,858,346.82
  投资活动产生的现金流量净额804,631,137.8563,937,249.03534,282,802.2736,373,293.07
三、筹资活动产生的现金流量:
  取得借款收到的现金389,103,542.67-724,942,840.01724,405,900.01
  筹资活动现金流入平衡项目0-00
  筹资活动现金流入小计389,103,542.67-724,942,840.01724,405,900.01
  偿还债务支付的现金447,000,000447,000,0001,179,380,0001,179,380,000
  分配股利、利润或偿付利息支付的现金894,947,519.9-1,528,602,067.26390,198,653.05
  其中:子公司支付给少数股东的股利、利润108,800,026.4-167,120,026.456,360,006.6
  支付其他与筹资活动有关的现金17,462,575.2-14,023,913.414,023,913.4
  筹资活动现金流出小计1,359,410,095.1447,000,0002,722,005,980.661,583,602,566.45
  筹资活动产生的现金流量净额-970,306,552.43-447,000,000-1,997,063,140.65-859,196,666.44
四、汇率变动对现金及现金等价物的影响-142,225.98-80,561.38140,062.36175,338.16
五、现金及现金等价物净增加额176,908,185.87110,467,108.22-584,683,775.84327,980,779.38
  加:期初现金及现金等价物余额773,576,445.84773,576,445.841,358,260,221.681,358,260,221.68
  期末现金及现金等价物余额950,484,631.71884,043,554.06773,576,445.841,686,241,001.06
补充资料:
  净利润395,191,400.94-999,992,847.58-
  资产减值准备-12,739,217.1-58,207,765.52-
  固定资产和投资性房地产折旧130,600,499.11-262,512,275.03-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧130,600,499.11-262,512,275.03-
  无形资产摊销6,627,441.02-12,439,838.81-
  长期待摊费用摊销3,065,974.29-6,026,473.54-
  处置固定资产、无形资产和其他长期资产的损失696,138.29--2,891,234.85-
  固定资产报废损失3,595,906.88-3,527,237.33-
  公允价值变动损失-10,582,063.21--15,171,586.8-
  财务费用199,964.52-10,000,229.83-
  投资损失-98,522,641.29--62,497,631.37-
  递延所得税19,759,878.06-6,457,511.49-
  其中:递延所得税资产减少-6,014,904.38-38,487,550.47-
    递延所得税负债增加25,774,782.44--32,030,038.98-
  存货的减少-419,107,984.56--317,321,310.24-
  经营性应收项目的减少253,219,825.18--423,098,940.65-
  经营性应付项目的增加109,756,150.44-333,297,801.22-
  其他-325.82--27,966,491.88-
  现金的期末余额950,484,631.71-773,576,445.84-
  减:现金的期初余额773,576,445.84-1,358,260,221.68-
  现金及现金等价物的净增加额176,908,185.87--584,683,775.84-
公告日期2026-08-292026-04-272026-03-282025-10-30
审计意见(境内)标准无保留意见
TOP↑